Loading...
•
Dec 31, 2021
CVRx Q4 2021 Earnings Report
CVRx's Q4 2021 financial performance more than doubled, driven by Barostim adoption and salesforce expansion.
Key Takeaways
CVRx reported a significant increase in revenue for Q4 2021, driven by the successful launch of Barostim for heart failure in the United States. Total revenue was $3.7 million, a 75% increase compared to the same period in the prior year. The company is focused on driving accelerated adoption by executing on its commercial strategy, which includes the continued expansion of its salesforce and the efforts to educate healthcare providers and consumers on the benefits of Barostim.
Revenue increased by 75% to $3.7 million compared to Q4 2020.
U.S. revenue increased by 244% to $2.9 million compared to Q4 2020.
U.S. HF revenue totaled $2.7 million, with 95 HF revenue units.
Gross profit increased by 63% to $2.7 million compared to Q4 2020.
CVRx
CVRx
CVRx Revenue by Geographic Location
Revenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.com Forward Guidance
The Company expects to report total revenue between $3.6 million and $4.0 million for the first quarter of 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income